Zhang H, Li Q, Liao Y, Ma D, Zeng F, Zhang Z
Int J Mol Sci. 2025; 25(24.
PMID: 39769249
PMC: 11678876.
DOI: 10.3390/ijms252413486.
Rossetti E, Vujadinovic M, van Huizen E, Tolboom J, Schuitemaker H, Yao F
PLoS One. 2024; 19(12):e0310250.
PMID: 39739963
PMC: 11687876.
DOI: 10.1371/journal.pone.0310250.
Vougiouklakis G, Agouridis A, Alexakis K, Mamilos A, Spernovasilis N
Cureus. 2024; 16(8):e66631.
PMID: 39258091
PMC: 11386367.
DOI: 10.7759/cureus.66631.
Dave V, Cardozo-Ojeda E, Mair F, Erickson J, Woodward-Davis A, Koehne A
J Immunol. 2021; 206(12):2937-2948.
PMID: 34088770
PMC: 8642491.
DOI: 10.4049/jimmunol.2100166.
Gehlhausen J, Iwasaki A
J Clin Invest. 2021; 131(9).
PMID: 33938452
PMC: 8087191.
DOI: 10.1172/JCI148300.
B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin.
Ford E, Sholukh A, Boytz R, Carmack S, Klock A, Phasouk K
J Clin Invest. 2021; 131(9).
PMID: 33784252
PMC: 8087200.
DOI: 10.1172/JCI142088.
Vaccines for Perinatal and Congenital Infections-How Close Are We?.
Singh T, Otero C, Li K, Valencia S, Nelson A, Permar S
Front Pediatr. 2021; 8:569.
PMID: 33384972
PMC: 7769834.
DOI: 10.3389/fped.2020.00569.
Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design.
Truong N, Smith J, Sandgren K, Cunningham A
Front Immunol. 2019; 10:373.
PMID: 30894859
PMC: 6414784.
DOI: 10.3389/fimmu.2019.00373.
Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.
Stanfield B, Kousoulas K
Curr Clin Microbiol Rep. 2016; 2(3):125-136.
PMID: 27114893
PMC: 4840408.
DOI: 10.1007/s40588-015-0020-4.
Antibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2.
Halford W, Geltz J, Messer R, Hasenkrug K
PLoS One. 2015; 10(12):e0145228.
PMID: 26670699
PMC: 4682860.
DOI: 10.1371/journal.pone.0145228.
Anti-glycoprotein g antibodies of herpes simplex virus 2 contribute to complete protection after vaccination in mice and induce antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Gorander S, Ekblad M, Bergstrom T, Liljeqvist J
Viruses. 2014; 6(11):4358-72.
PMID: 25398047
PMC: 4246227.
DOI: 10.3390/v6114358.
A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.
Stanfield B, Stahl J, Chouljenko V, Subramanian R, Charles A, Saied A
PLoS One. 2014; 9(10):e109890.
PMID: 25350288
PMC: 4211657.
DOI: 10.1371/journal.pone.0109890.
Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
Cuburu N, Wang K, Goodman K, Pang Y, Thompson C, Lowy D
J Virol. 2014; 89(1):83-96.
PMID: 25320297
PMC: 4301134.
DOI: 10.1128/JVI.02380-14.
Prophylactic and therapeutic modulation of innate and adaptive immunity against mucosal infection of herpes simplex virus.
Uyangaa E, Patil A, Eo S
Immune Netw. 2014; 14(4):187-200.
PMID: 25177251
PMC: 4148489.
DOI: 10.4110/in.2014.14.4.187.
Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.
Gorander S, Harandi A, Lindqvist M, Bergstrom T, Liljeqvist J
J Virol. 2012; 86(14):7544-53.
PMID: 22553328
PMC: 3416275.
DOI: 10.1128/JVI.00186-12.
The Role of Plasmacytoid Dendritic Cells in Innate and Adaptive Immune Responses against Alpha Herpes Virus Infections.
Schuster P, Boscheinen J, Tennert K, Schmidt B
Adv Virol. 2012; 2011:679271.
PMID: 22312349
PMC: 3265311.
DOI: 10.1155/2011/679271.
Innate and adaptive immune responses to herpes simplex virus.
Chew T, Taylor K, Mossman K
Viruses. 2011; 1(3):979-1002.
PMID: 21994578
PMC: 3185534.
DOI: 10.3390/v1030979.
Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.
Khodai T, Chappell D, Christy C, Cockle P, Eyles J, Hammond D
Clin Vaccine Immunol. 2011; 18(10):1702-9.
PMID: 21852545
PMC: 3187041.
DOI: 10.1128/CVI.05071-11.
Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection.
Conrady C, Halford W, Carr D
J Virol. 2010; 85(4):1625-33.
PMID: 21147921
PMC: 3028887.
DOI: 10.1128/JVI.01715-10.
A mucosal vaccination approach for herpes simplex virus type 2.
Tirabassi R, Ace C, Levchenko T, Torchilin V, Selin L, Nie S
Vaccine. 2010; 29(5):1090-8.
PMID: 21134447
PMC: 3035179.
DOI: 10.1016/j.vaccine.2010.11.076.